Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Klarna Group plc due to allegations of violations of federal securities laws related to misleading statements and inadequate disclosures regarding loss reserves following its IPO [2][5]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses in Klarna to contact them to discuss their legal options, particularly in light of a federal securities class action with a deadline for lead plaintiff applications on February 20, 2026 [2][5]. - The complaint alleges that Klarna and its executives materially understated the risk of increased loss reserves shortly after the IPO, which they either knew or should have known [5][6]. - The lawsuit claims that when the true details about Klarna's financial situation became public, investors suffered damages due to the misleading nature of the company's public statements [5][6]. Group 2: Financial Performance and Market Reaction - Klarna reported a net loss of $95 million in its first earnings report since going public, while setting aside $235 million for loan loss provisions, exceeding analyst estimates of $215.8 million [6]. - Provisions for loan losses represented 0.72% of gross merchandise volume, an increase from 0.44% a year ago, indicating a growing concern over credit risk [6]. - Following the earnings report, Klarna's stock experienced a decline of 9.3% on November 18, 2025, reflecting negative market sentiment regarding its financial health [6].

Core Viewpoint - Fermi Inc. is facing potential legal claims due to allegations of misleading statements regarding its Project Matador campus and tenant commitments, which have led to significant stock price declines following the termination of a key funding agreement [5][8]. Group 1: Company Overview - Fermi Inc. (NASDAQ: FRMI) completed its initial public offering on October 1, 2025, offering approximately 32.5 million shares at $21.00 per share [6]. - The company aimed to develop a large electric generation campus for AI data centers and had identified a "First Tenant" for its Project Matador site [6]. Group 2: Legal Issues - A federal securities class action has been filed against Fermi, with a deadline of March 6, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Fermi and its executives violated federal securities laws by making false or misleading statements about tenant demand and funding commitments for Project Matador [5]. Group 3: Financial Impact - In November 2025, Fermi announced that the First Tenant had agreed to advance up to $150 million toward construction costs, which was a significant funding arrangement for the project [7]. - Following the termination of the Advance in Aid of Construction Agreement on December 12, 2025, Fermi's stock price fell more than 33%, closing at $10.09 per share, significantly below the IPO price [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Bitdeer Technologies Group due to alleged violations of federal securities laws, encouraging affected investors to contact them for legal options [2][4]. Group 1: Allegations Against Bitdeer - The complaint alleges that Bitdeer and its executives made false and misleading statements regarding the mass production of its fourth-generation SEALMINER (A4) rigs, specifically about the expected energy efficiency of the SEAL04 ASIC chip [4]. - It is claimed that Bitdeer failed to disclose that the SEAL04 chip, projected to have an energy efficiency of 5 J/TH, would not be ready for use in A4 rigs until mass production was expected to begin in Q2 2025 [4]. Group 2: Financial Performance and Stock Impact - On November 10, 2025, Bitdeer reported a third-quarter earnings per share of -$1.28, missing the consensus estimate of -$0.22, and disclosed significant delays in the development of its next-generation Seal 04 ASIC chip [5]. - Following this announcement, Bitdeer's stock price fell by $2.63 per share, or 14.9%, closing at $15.02 on November 11, 2025 [5]. - A subsequent fire incident at Bitdeer's under-construction facility in Ohio on November 11, 2025, led to another stock price drop of $2.83 per share, or 20.3%, closing at $11.11 on November 13, 2025 [6]. Group 3: Legal Proceedings and Class Action - Investors who purchased Bitdeer securities between June 6, 2024, and November 10, 2025, are reminded of the February 2, 2026 deadline to seek the role of lead plaintiff in the federal securities class action against the company [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 4: Call for Information - Faruqi & Faruqi encourages anyone with information regarding Bitdeer's conduct, including whistleblowers and former employees, to contact the firm [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Bitdeer Technologies Group due to alleged violations of federal securities laws, encouraging affected investors to come forward before the February 2, 2026 deadline for lead plaintiff applications [2][4]. Group 1: Allegations and Financial Performance - The complaint alleges that Bitdeer and its executives made false or misleading statements regarding the mass production of their fourth-generation SEALMINER (A4) rigs, specifically about the expected energy efficiency of the SEAL04 ASIC chip [4]. - Bitdeer reported a third-quarter 2025 earnings per share of -$1.28, significantly missing the consensus estimate of -$0.22, and disclosed delays in the development of the next-generation Seal 04 ASIC chip [5]. - Following the earnings report, Bitdeer's stock price fell by $2.63 per share, or 14.9%, closing at $15.02 on November 11, 2025 [5]. Group 2: Incident and Stock Impact - On November 12, 2025, Bitdeer reported a fire incident at its under-construction facility in Massillon, Ohio, which caused damage to 2 of the 26 buildings [6]. - The stock price dropped another $2.83 per share, or 20.3%, closing at $11.11 on November 13, 2025, following the fire incident announcement [6]. Group 3: Legal Proceedings and Investor Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of class members, overseeing the litigation on behalf of the class [7]. - Faruqi & Faruqi encourages anyone with information regarding Bitdeer's conduct, including whistleblowers and former employees, to contact the firm [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Bitdeer Technologies Group due to alleged violations of federal securities laws related to misleading statements about the company's SEALMINER A4 project and its delayed chip development [2][4]. Financial Performance - Bitdeer reported a third-quarter earnings per share of -$1.28, which significantly missed the consensus estimate of -$0.22, leading to a stock price drop of $2.63 (14.9%) to close at $15.02 on November 11, 2025 [5]. - Following a fire incident at its construction facility, Bitdeer's stock fell an additional $2.83 (20.3%) to close at $11.11 on November 13, 2025 [6]. Legal Proceedings - A federal securities class action has been filed against Bitdeer, with a deadline of February 2, 2026, for investors to seek the role of lead plaintiff [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [7]. Company Background - Faruqi & Faruqi, LLP is a national securities law firm that has recovered hundreds of millions of dollars for investors since its establishment in 1995 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal rights [1]. - There is a deadline of December 8, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against aTyr [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about Efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [4]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [5]. - The study reported that complete steroid withdrawal was achieved in 52.6% of patients treated with efzofitimod versus 40.2% on placebo [5]. Group 3: Market Impact - Following the release of the study results, aTyr's stock price plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Bitdeer Technologies Group due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's SEALMINER A4 project and its delayed product development [4][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Bitdeer to contact them for discussing legal options, particularly for those who purchased securities between June 6, 2024, and November 10, 2025 [1][4]. - A federal securities class action has been filed against Bitdeer, with a deadline of February 2, 2026, for investors to seek the role of lead plaintiff [4][9]. - The complaint alleges that Bitdeer and its executives made false statements regarding the readiness and efficiency of the SEAL04 chip, which was expected to be used in the A4 rigs [6]. Group 2: Financial Performance and Stock Impact - Bitdeer reported a third-quarter earnings per share of -$1.28, significantly missing the consensus estimate of -$0.22, which led to a stock price drop of $2.63 per share, or 14.9%, closing at $15.02 on November 11, 2025 [7]. - Following a fire incident at its under-construction facility in Ohio, Bitdeer's stock fell another $2.83 per share, or 20.3%, closing at $11.11 on November 13, 2025 [8]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed adverse facts affecting the company's financial performance [2][5]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Molina to contact them regarding their legal options, particularly for those who purchased securities between February 5, 2025, and July 23, 2025 [1][2]. Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements and failed to disclose critical information, including: - Material adverse facts about the company's medical cost trend assumptions [5]. - A dislocation between premium rates and medical costs [5]. - Dependency on low utilization of behavioral health, pharmacy, and inpatient and outpatient services for near-term growth [5]. - Likelihood of substantial cuts to financial guidance for fiscal year 2025 [5]. - Misleading positive statements regarding the company's business and prospects [5]. Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures, leading to a 10.2% cut in full-year earnings guidance from at least $24.50 to a range of $21.50 to $22.50 per share [6]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [6]. - On July 23, 2025, Molina further slashed its full-year earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and cutting full-year adjusted earnings guidance to no less than $19.00 per diluted share, representing a 13.6% reduction [7][8]. - This led to a significant drop in Molina's stock price by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of false and misleading statements regarding its product SLK, which failed to demonstrate competitive efficacy compared to BIMZELX, leading to a significant stock price drop [1][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in MoonLake between March 10, 2024, and September 29, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against MoonLake, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [1][5]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose material facts about the differences between Nanobodies and monoclonal antibodies [3]. - Specific allegations include that SLK and BIMZELX share the same molecular targets, and that SLK's unique structure does not provide superior clinical benefits or efficacy [3]. Group 3: Stock Performance Impact - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which showed SLK's lack of competitive efficacy, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper controls in manufacturing processes [3][5]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Jasper [3]. - Investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, are encouraged to contact the firm to discuss their legal rights [1][3]. Group 2: Allegations Against Jasper - The complaint alleges that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products, including briquilimab [5]. - The failure to disclose these issues has led to overstated business and financial prospects for Jasper, making public statements materially false and misleading [5]. Group 3: Impact of Recent Developments - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, leading to a significant drop in stock price by $3.73 per share, or 55.1%, closing at $3.04 per share [6]. - The company announced a halt in the ETESIAN Study and paused development in asthma and SCID, alongside plans for cost-cutting measures and potential restructuring to extend its financial runway [6].